drugset / Trial / NCT00105521
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Timeline
- Start
- 2004-09-30
- Primary completion
- 2006-03-31
- Completion
- 2006-03-31
Publications
- Background Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226.
- Background Goetz CG, Laska E, Hicking C, Damier P, Muller T, Nutt J, Warren Olanow C, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15;23(5):700-7. doi: 10.1002/mds.21897.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sarizotan | Small molecule | 2 mg | Oral |
| Subject | Sarizotan | Small molecule | 4 mg | Oral |
| Subject | Sarizotan | Small molecule | 10 mg | Oral |